[CAS NO. 1026680-07-8] LB-100
Please click "REQUEST A QUOTE" button if you need other sizes or
custom synthesis
request a quote
If there is no stock, or you need other sizes or custom synthesis,
please:
PRODUCTS SPECIFICATIONS [1026680-07-8]
Catelog
SLK-S7537
Brand
Selleck
CAS
1026680-07-8
DESCRIPTION [1026680-07-8]
Overview
| MDL | - |
|---|---|
| Molecular Weight | 268.31 |
| Molecular Formula | C13H20N2O4 |
| SMILES | CN1CCN(CC1)C(=O)C2C3CCC(C2C(=O)O)O3 |
For research use only.
Storage
3 years,-20°C,powder
1 years,-80°C,in solvent
1 years,-80°C,in solvent
Shipping
Room temperature shipping(Stability testing shows this product can be shipped without any cooling measures.)
Preparing Stock Solutions
| 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.7270 mL | 18.6352 mL | 37.2703 mL |
| 5 mM | 0.7454 mL | 3.7270 mL | 7.4541 mL |
| 10 mM | 0.3727 mL | 1.8635 mL | 3.7270 mL |
| 50 mM | 0.0745 mL | 0.3727 mL | 0.7454 mL |
Description
LB-100 is a water soluble inhibitor with IC50s of 0.85 μM and 3.87 μM in BxPc-3 and Panc-1 cells.
Targets
| PP2A [1] |
In vitro
LB-100 inhibits the cell growth with IC50 of 2.3 μM (in BxPc-3) or 1.7 μM (in Panc-1 cell). In BxPc-3, Panc-1, and SW1990 cells, LB-100 reduces the PP2A activity by 30-50%. LB-100 increases concentration of doxorubicin within cells (2.5 fold to control) and sensitizes tumor cells to the cytotoxicity of doxorubicin. LB-100 increaseds VEGF secretion, and thus enhances HIF-1α-VEGF mediated angiogenesis.
In vivo
In a mouse pancreatic cancer xenograft model, LB-100 (2 mg/kg, i.p.) enhances chemotherapy of doxorubicin. LB-100 causes higher density of microvessel in tumors and rapid blood flow at the surface of tumors.
Powered by Arctom Copyright © 2025 Arctom.
All rights reserved.